Literature DB >> 9314829

Monomeric phospholamban overexpression in transgenic mouse hearts.

G Chu1, G W Dorn, W Luo, J M Harrer, V J Kadambi, R A Walsh, E G Kranias.   

Abstract

Phospholamban, a prominent modulator of the sarcoplasmic reticulum (SR) Ca(2+)-ATPase activity and basal contractility in the mammalian heart, has been proposed to form pentamers in native SR membranes. However, the monomeric form of phospholamban, which is associated with mutating Cys41 to Phe41, was shown to be as effective as pentameric phospholamban in inhibiting Ca2+ transport in expression systems. To determine whether this monomeric form of phospholamban is also functional in vivo, we generated transgenic mice with cardiac-specific overexpression of the mutant (Cys41-->Phe41) phospholamban. Quantitative immunoblotting indicated a 2-fold increase in the cardiac phospholamban protein levels compared with wild-type controls, with approximately equal to 50% of phospholamban migrating as monomers and approximately 50% as pentamers upon SDS-PAGE. The mutant-phospholamban transgenic hearts were analyzed in parallel with transgenic hearts overexpressing (2-fold) wild-type phospholamban, which migrated as pentamers upon SDS-PAGE. SR Ca(2+)-uptake assays revealed that the EC50 values for Ca2+ were as follows: 0.32 +/- 0.01 mumol/L in hearts overexpressing monomeric phospholamban, 0.49 +/- 0.05 mumol/L in hearts overexpressing wild-type phospholamban, and 0.26 +/- 0.01 mumol/L in wild-type control mouse hearts. Analysis of cardiomyocyte mechanics and Ca2+ kinetics indicated that the inhibitory effects of mutant-phospholamban overexpression (mt) were less pronounced than those of wild-type phospholamban overexpression (ov) as assessed by depression of the following: (1) shortening fraction (25% mt versus 45% ov), (2) rates of shortening (27% mt versus 48% ov), (3) rates of relengthening (25% mt versus 50% ov) (4) amplitude of the Ca2+ signal (21% mt versus 40% ov), and (5) time for decay of the Ca2+ signal (25% mt versus 106% ov) compared with control (100%) myocytes. The differences in basal cardiac, myocyte mechanics and Ca2+ transients among the animal groups overexpressing monomeric or wild-type phospholamban and wild-type control mice were abolished upon isoproterenol stimulation. These findings suggest that pentameric assembly of phospholamban is important for mediating its optimal regulatory effects on myocardial contractility in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314829     DOI: 10.1161/01.res.81.4.485

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

1.  Mapping the energy surface of transmembrane helix-helix interactions.

Authors:  J Torres; A Kukol; I T Arkin
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

2.  Structural dynamics and topology of phosphorylated phospholamban homopentamer reveal its role in the regulation of calcium transport.

Authors:  Vitaly V Vostrikov; Kaustubh R Mote; Raffaello Verardi; Gianluigi Veglia
Journal:  Structure       Date:  2013-10-24       Impact factor: 5.006

3.  Ventricular function during exercise in mice and rats.

Authors:  Heidi L Lujan; Hussein Janbaih; Han-Zhong Feng; Jian-Ping Jin; Stephen E DiCarlo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-19       Impact factor: 3.619

4.  Modulation of focal and global Ca2+ release in calsequestrin-overexpressing mouse cardiomyocytes.

Authors:  W Wang; L Cleemann; L R Jones; M Morad
Journal:  J Physiol       Date:  2000-04-15       Impact factor: 5.182

Review 5.  Phospholamban and sarcolipin: Are they functionally redundant or distinct regulators of the Sarco(Endo)Plasmic Reticulum Calcium ATPase?

Authors:  Sana A Shaikh; Sanjaya K Sahoo; Muthu Periasamy
Journal:  J Mol Cell Cardiol       Date:  2015-12-29       Impact factor: 5.000

6.  In vivo phosphorylation of cardiac troponin I by protein kinase Cbeta2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts.

Authors:  Y Takeishi; G Chu; D M Kirkpatrick; Z Li; H Wakasaki; E G Kranias; G L King; R A Walsh
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.